Akcea is a biopharmaceutical company that develops RNA-targeted antisense therapeutics for the treatment of cardiometabolic lipid disorders.
Business Model:
Revenue: $489M
Employees: 201-500
Akcea was acquired by
Ionis Pharmaceuticals.
The acquisition happend on 2020-08-31.
Details of the transaction were not public
Address: 22 Boston Wharf Road
City: Boston
State: MA
Zip: 02210
Country: US
Akcea is a biopharmaceutical company that develops RNA-targeted antisense therapeutics for the treatment of cardiometabolic lipid disorders.
Contact Phone:
+16172070202
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
7/14/2017
IPO Valuation:
$514M
Ticker Symbol:
AKCA
IPO Price:
$8/share
Amount Raised:
$125M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 12/2015 | Equity | $543.2M | 7/2017 | IPO | $125M |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|